Evidence map›Paper›PMID 31171879›Full record

Trial reportNature medicine2019

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Matteo S Carlino, Rosalie Fisher, Georgina V Long, F Stephen Hodi, Jennifer Tsoi and 7 more

Erratum issued Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02130466 (A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma), which is not on this map. Cited by 205 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 2 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02130466 phase1 / phase2completednot on this map

A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2014 to 2021Enrolled184ConditionsMelanoma, Solid TumorsArmsPembrolizumab, Dabrafenib, Trametinib, Placebo
3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 2 syntheses or guidelines pooled it, 316 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Anti-PD-1 Combinations: Triplets and Beyond.Current oncology reports · 2026
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 4 countries.

Antoni RibasUniversity of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
Donald LawrenceMassachusetts General Hospital, Boston, MA, USA.
Victoria AtkinsonGallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
Sachin AgarwalIndiana University Health Goshen Center for Cancer Care, Goshen, IN, USA.
Wilson H MillerSegal Cancer Centre, Montreal, Quebec, Canada.
Matteo S CarlinoWestmead Hospital, Sydney, New South Wales, Australia.
Rosalie FisherAuckland District Health Board, Auckland, New Zealand.
Georgina V LongThe University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8894-3545
F Stephen HodiDana-Farber Cancer Institute, Boston, MA, USA.
Jennifer TsoiUniversity of California, Los Angeles, Los Angeles, CA, USA.
Catherine S GrassoUniversity of California, Los Angeles, Los Angeles, CA, USA.
Bijoyesh MookerjeeNovartis, East Hanover, NJ, USA.
Qing ZhaoMerck & Co., Inc., Kenilworth, NJ, USA.
Razi GhoriMerck & Co., Inc., Kenilworth, NJ, USA.
Blanca Homet MorenoMerck & Co., Inc., Kenilworth, NJ, USA.
Nageatte IbrahimMerck & Co., Inc., Kenilworth, NJ, USA.
Omid HamidThe Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of California, Los Angeles · USThe University of Sydney · AUAngeles Clinic and Research Institute · USAuckland District Health Board · NZDana-Farber Cancer Institute · USGreenslopes Private Hospital · AUIndiana University Health · USJewish General Hospital · CAMassachusetts General Hospital · USNovartis (United States) · US

Funding

Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
NCI NIH HHS P01 CA168585NCI NIH HHS R35 CA197633
6 · The paper itself

Abstract

Oncogene-targeted therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors induces a high initial response rate in patients with BRAF

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImidazolesImmunotherapyMaleMAP Kinase Kinase KinasesMelanomaMiddle AgedMutationOximesProtein Kinase InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBRAF protein, humandabrafenibImidazolesMAP Kinase Kinase KinasesMAS1 protein, humanOximespembrolizumabProtein Kinase InhibitorsProto-Oncogene MasProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Identifiers

PMID31171879
PMCPMC8562134
OpenAlexW2948884915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.